[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Mark Guinan Biography and Net Worth

CFO of Quest Diagnostics

Mark J. Guinan serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Guinan joined the Company in July 2013. From 2010 until joining Quest Diagnostics in 2013, he served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the health care industry. Mr. Guinan has served as a director of Myovant Sciences, Ltd. since July 2018. Previously, he had served in a number of finance and operations roles in a long career at Johnson & Johnson including 2009 to 2010 as Vice President, Chief Procurement Officer, and 2005 to 2009 as Vice President, Group Finance Pharmaceuticals. Before joining Johnson & Johnson in 1997, he held a number of financial roles at Procter & Gamble.

What is Mark Guinan's net worth?: The estimated net worth of Mark Guinan is at least $25.27 million as of December 24th, 2020. Mr. Guinan owns 155,335 shares of Quest Diagnostics stock worth more than $25,273,005 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Guinan may own. Learn More about Mark Guinan's net worth.
How do I contact Mark Guinan?: The corporate mailing address for Mr. Guinan and other Quest Diagnostics executives is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. Quest Diagnostics can also be reached via phone at (973) 520-2700 and via email at [email protected]. Learn More on Mark Guinan's contact information.
Has Mark Guinan been buying or selling shares of Quest Diagnostics?: Mark Guinan has not been actively trading shares of Quest Diagnostics during the last ninety days. Most recently, Mark Guinan sold 81,756 shares of the business's stock in a transaction on Thursday, December 24th. The shares were sold at an average price of $120.37, for a transaction totalling $9,840,969.72. Following the completion of the sale, the chief financial officer now directly owns 155,335 shares of the company's stock, valued at $18,697,673.95. Learn More on Mark Guinan's trading history.
Who are Quest Diagnostics' active insiders?: Quest Diagnostics' insider roster includes Mark Delaney (SVP), Michael Deppe (CAO), Catherine Doherty (SVP), Vicky Gregg (Director), Mark Guinan (CFO), Karthik Kuppusamy (SVP), Michael Prevoznik (SVP), Timothy Ring (Director), Stephen Rusckowski (CEO), Daniel Stanzione (Director), and Gail Wilensky (Director). Learn More on Quest Diagnostics' active insiders.
Are insiders buying or selling shares of Quest Diagnostics?: In the last twelve months, insiders at the medical research company sold shares 10 times. They sold a total of 39,850 shares worth more than $5,692,423.40. The most recent insider tranaction occured on November, 6th when CAO Michael J Deppe sold 18,755 shares worth more than $2,889,207.75. Insiders at Quest Diagnostics own 0.8% of the company. Learn More about insider trades at Quest Diagnostics.
Information on this page was last updated on 11/6/2024.

Mark Guinan Insider Trading History at Quest Diagnostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/24/2020	Sell	81,756	$120.37	$9,840,969.72	155,335
6/13/2019	Sell	73,005	$100.00	$7,300,500.00	139,022
5/25/2018	Sell	61,533	$105.71	$6,504,653.43	119,733
5/5/2014	Buy	4,000	$55.51	$222,040.00	44,222

Mark Guinan Buying and Selling Activity at Quest Diagnostics

Quest Diagnostics Company Overview

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Today's Range

Now: $162.70

$160.33

$163.08

50 Day Range

MA: $154.47

$146.83

$162.11

2 Week Range

Now: $162.70

$123.04

$163.08

Volume

121,200 shs

Average Volume

918,985 shs

Market Capitalization

$18.16 billion

P/E Ratio

21.87

Dividend Yield

1.86%

Beta

0.89